Compare iShares Core MSCI EAFE ETF (IEFA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Repligen Corporation Common Stock — how do they compare? iShares Core MSCI EAFE ETF trades at $95.53 (market cap $188.94B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 17× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares Core MSCI EAFE ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Repligen Corporation Common Stock for 0 Days on average.
| IEFA | RGEN | |
|---|---|---|
Market Cap | $188.94B | $11.14B |
Volume | 6,200,262 | 1,259,263 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $194.57 |
52-Week Low | $85.06 | $102.87 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.64, up 0.48% on the day, while technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights its size advantage and higher dividend yield compared to peers, though some competitors have shown stronger recent returns.
The outlook for IEFA is mixed, with bearish technicals offset by its low-cost, diversified international exposure. Opportunities include defensive shifts in investor flows away from concentrated U.S. tech, while risks involve underperformance versus broader global funds and capped upside in strategies like covered calls on the ETF.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
